Tritiated thymidine as a broad spectrum initiator in transplacental two-stage carcinogenesis, with phorbol as promoter.
A single subcutaneous injection of 200 mu Ci [3H] thymidine into pregnant BALD/c mice, followed by intraperitoneal injections of phorbol, twice weekly for 25 weeks, in the offspring, resulted in higher tumour development in the lungs and livers of male and, to a lesser extent, of female offspring, than in their untreated littermates. The difference in overall tumour incidence was statistically significant, but the increases of the individual tumour types were only of borderline significance. Slight carcinogenic activity of [3H]thymidine alone was observed in the mothers, and in the offspring, without phorbol treatment. The results suggest the possibility of using [3H]thymidine as a broad spectrum initiator for transplacental two-stage carcinogenicity studies to determine the organ specificity of different promoting agents.
D000236:Adenoma / Q000139:chemically induced; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced; D005260:Female; D008113:Liver Neoplasms / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000139:chemically induced*; D008223:Lymphoma / Q000139:chemically induced; D008297:Male; D008431:Maternal-Fetal Exchange; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000139:chemically induced; D010703:Phorbol Esters; D010704:Phorbols; D011247:Pregnancy; D013936:Thymidine; D014316:Tritium
D010703:Phorbol Esters; D010704:Phorbols; D014316:Tritium; D013936:Thymidine